EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Novel and Emerging Biomarkers in the Diagnosis and Management of Kidney Disease in Cirrhosis

Elizabeth Reznik, Deirdre Reidy, Xiaohan Ying, Emily Schonfeld, Arun Jesudian

Journal of Gastrointestinal and Liver Diseases · 27.06.2026 · 35 (2) · 263-275

DOI: 10.15403/jgld-6647 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, online erschienen am 27.06.2026. Verfasst von Elizabeth Reznik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, New York University Langone Hospital, New York, USA. elizabeth.reznik@nyulangone.org. Hauptthemen laut MEDLINE: Liver Cirrhosis, Acute Kidney Injury, Renal Insufficiency, Chronic, Kidney. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute kidney injury (AKI) and chronic kidney disease (CKD) are common conditions among patients with cirrhosis whose development is associated with increased morbidity and mortality. Recurrent episodes of AKI within this population can ultimately lead to CKD, while patients with underlying CKD are in turn more likely to experience AKI. Determining the etiology of kidney dysfunction in the setting of cirrhosis is often challenging given the considerable limitations of currently available diagnostic tools. Ongoing research into the role of novel serum and urine biomarkers may allow for more timely diagnosis and treatment of kidney injury among patients with cirrhosis. This review provides an overview of kidney dysfunction in cirrhosis with a focus on the role of these emerging biomarkers for diagnosis of AKI and CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisAcute Kidney InjuryRenal Insufficiency, ChronicKidneyHumansBiomarkersPredictive Value of TestsPrognosisLipocalin-2

Substanzen

BiomarkersLipocalin-2

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, New York University Langone Hospital, New York, USA. elizabeth.reznik@nyulangone.org.
  • Department of Gastroenterology and Hepatology, NewYork- Presbyterian, Weill Cornell, United States of America. dif9035@nyp.org.
  • Department of Gastroenterology and Hepatology, NewYork- Presbyterian, Weill Cornell, United States of America. xiy4001@nyp.org.
  • Department of Gastroenterology and Hepatology, NewYork- Presbyterian, Weill Cornell, United States of America. eas9021@med.cornell.edu.
  • Department of Gastroenterology and Hepatology, NewYork- Presbyterian, Weill Cornell, United States of America. abj9004@med.cornell.edu.

Zitieren

APA

Reznik, E., Reidy, D., Ying, X., Schonfeld, E., & Jesudian, A. (2026). Novel and Emerging Biomarkers in the Diagnosis and Management of Kidney Disease in Cirrhosis. Journal of Gastrointestinal and Liver Diseases, 35(2), 263-275. https://doi.org/10.15403/jgld-6647

Vancouver

Reznik E, Reidy D, Ying X, Schonfeld E, Jesudian A. Novel and Emerging Biomarkers in the Diagnosis and Management of Kidney Disease in Cirrhosis. Journal of Gastrointestinal and Liver Diseases. 2026;35(2):263-275. doi:10.15403/jgld-6647

BibTeX
@article{Reznik2026,
  author = {Reznik, Elizabeth and Reidy, Deirdre and Ying, Xiaohan and Schonfeld, Emily and Jesudian, Arun},
  title = {Novel and Emerging Biomarkers in the Diagnosis and Management of Kidney Disease in Cirrhosis},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2026},
  volume = {35},
  number = {2},
  pages = {263--275},
  doi = {10.15403/jgld-6647}
}
Kostenlos starten →